This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel Vitt, CEO of Immunic.

Times:

02:54 Immunic

24:04 Neurvati Neurosciences/GRIN Therapeutics

GRIN Therapeutics

GRIN Therapeutics Inc. is dedicated to the research and development of precision therapeutics for neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.

In 2024, GRIN Therapeutics reported promising topline data from a phase 1b/2a clinical trial evaluating investigational radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function variants, leading to the dec ...